Active ingredientIptacopanCat. No. P-I074-001CAS 1644670-37-0Family · Pharmaceutical analytical standards
Iptacopan
An oral complement factor B inhibitor, approved in 2023 in the United States and in 2024 in the European Union for paroxysmal nocturnal haemoglobinuria; in the United States it is also indicated for IgA nephropathy and C3 glomerulopathy. This family brings together the active ingredient, metabolites and labelled standards.
Did you know?The FDA considers it the first of a new class: it blocks factor B, a key protein of the alternative complement pathway, upstream of C3 cleavage.
Go to the active ingredient →Active ingredientIptacopanCat. No. P-I074-001CAS 1644670-37-0
MetaboliteIptacopan Acyl GlucuronideCat. No. P-I074-002
Isotopically labelledIptacopan-13C-d3Cat. No. P-I074-003No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.